Anti-HB-EGF antibody

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAnti-HB-EGF antibody
Drug Alias NameU3-1565
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHeparin-binding EGF-like growth factor inhibitors
TargetsHeparin-binding EGF-like growth factor
Therapy Area/IndicationsSolid tumoursOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesU3 PharmaAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A